Universitätsklinikum Heidelberg

The Work- and Further Training Situation of young Doctors in Further Training in Gynecology - A Standpoint (2020) Lermann J, Knabl J, Neimann J, Schulte K, Proske K, Schott S, Raspe M Conference contribution Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article Evaluation of pregnancies after allogeneic stem cell transplantation during the last 15years in Germany (2020) Sockel K, Frank S, Neu A, Ditschkowski M, Hilgendorf I, Goeckenjan M, Stoelzel F, et al. Conference contribution Allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia with ASXL1-, RUNX1- and TP53 mutations (2020) Egger-Heidrich K, Middeke JM, Schaefer-Eckart K, Kaufmann M, Einsele H, Mueller-Tidow C, Rösler W, et al. Conference contribution Real-world management and outcome of thymic carcinomas in a tertiary German thoracic oncology center (2020) Margineanu A, Bulut E, Rieker R, Winter H, Eichhorn M, Heussel CP, Herth F, et al. Conference contribution Registry Research Funding of the German Society of Plastic, Reconstructive and Aesthetic Surgeons (DGPRaC) and Research Funding Report 2019/2020 (2020) Moellhoff N, Prantl L, Behr B, Beier JP, Daigeler A, Dragu A, Eisenhardt SU, et al. Journal article Mycobacterial Cord Factor Reprograms the Macrophage Response to IFN-γ towards Enhanced Inflammation yet Impaired Antigen Presentation and Expression of GBP1 (2020) Huber A, Killy B, Grummel N, Bodendorfer B, Paul S, Wiesmann V, Naschberger E, et al. Journal article, Original article Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, et al. Journal article CAMK1D triggers immune resistance of human tumor cells refractory to anti-PD-L1 treatment (2020) Volpin V, Michels T, Sorrentino A, Menevse AN, Knoll G, Ditz M, Milenkovic VM, et al. Journal article Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020) Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. Conference contribution